(COMUNICADO DE PRENSA) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionero mundial en productos farmacéuticos y diagnóstico centrado en el avance de la ciencia para mejorar la vida de las personas, ha anunciado que la Comisión Europea ha aprobado Xofluza (baloxavir marboxil), un nuevo fármaco antiviral contra la gripe, para el tratamiento y la prevención de la gripe en niños a partir de un año . Xofluza es el primer antiviral contra la influenza con un nuevo mecanismo de acción en casi 20 años y puede detener la replicación viral más rápido que el oseltamivir. El fármaco se toma en una sola dosis, lo que ayuda a reducir la carga social de la gripe al ayudar a los pacientes a recuperarse rápidamente y al prevenir la infección en las personas después del contacto con alguien que tiene el virus. Es el primer medicamento antigripal oral de dosis única aprobado en Europa para niños.
“Estamos encantados de que la Comisión Europea haya aprobado Xofluza para niños a partir de un año de edad, ya que la gripe puede ser particularmente peligrosa para los niños más pequeños”, dijo Levi Garraway, M.D., Ph.D., director médico y director de Roche de Desarrollo Global de Productos. “Esperamos que el conveniente régimen oral de dosis única de Xofluza ayude a los niños a recuperarse rápidamente, así como a reducir la carga social de la influenza”.
La gripe es una enfermedad infecciosa grave y representa una amenaza importante para la salud pública.4-6 Las tasas de gripe en Europa están aumentando y se espera que el virus infecte a uno de cada cuatro niños cada año .6,7 Además de tener un mayor riesgo de infección, los niños también juegan un papel importante en la transmisión de la influenza de una persona a otra.6,8 En estudios de transmisión de la influenza en los hogares, el riesgo de infección de otras personas en el hogar llegó al 38 %.9 El tratamiento profiláctico con Xofluza, que detiene la replicación viral más rápido que el oseltamivir, puede ayudar a limitar la propagación de la influenza y, por lo tanto, reducir el impacto y la carga de la influenza en la sociedad.2,10,11
La aprobación se basa en los resultados de los estudios de fase III miniSTONE-2 y BLOCKSTONE.1,2 El estudio miniSTONE-2 cumplió su objetivo principal de seguridad y mostró que Xofluza redujo el tiempo de liberación de la influenza del cuerpo en más de dos días en comparación con el oseltamivir (replicación viral; mediana de tiempo de 24,2 horas frente a 75,8 horas, respectivamente). Xofluza fue bien tolerado y no se identificaron nuevas señales de seguridad.1
En el estudio BLOCKSTONE, Xofluza mostró un efecto profiláctico estadísticamente significativo después de una dosis oral única, al reducir el riesgo de que las personas desarrollen influenza después de la exposición a un miembro del hogar infectado en un 86 % en comparación con el placebo (1,9 % en los participantes tratados con Xofluza y 13,6 % en los grupo placebo).2
Xofluza fue aprobado por primera vez para su uso en Europa en 2021 para el tratamiento de la influenza no complicada y para la profilaxis posterior a la exposición de la influenza en adultos y adolescentes a partir de 12 años.12 Xofluza ahora está aprobado en más más de 70 países para el tratamiento de los tipos de influenza A y B.13 Roche continúa investigando Xofluza en ensayos de fase III en niños menores de un año (NCT03653364), así como evaluando su potencial para reducir la transmisión de la influenza de una persona infectada a los miembros del hogar (NCT03969212).14,15
Acerca de miniSTONE-21
miniSTONE-2 fue un estudio de fase III, multicéntrico, aleatorizado, doble ciego que evaluó la seguridad, la farmacocinética y la eficacia de una dosis única de Xofluza® (baloxavir marboxil) en comparación con oseltamivir en niños sanos de uno a menos de 12 años. con infección gripal y mostrando síntomas gripales durante no más de 48 horas (temperatura de 38°C o más, y uno o más síntomas respiratorios).
Los participantes inscritos en el estudio fueron reclutados en paralelo en dos cohortes: niños de cinco a menos de 12 años y niños de uno a menos de cinco años. Los participantes fueron asignados al azar para recibir una dosis única de Xofluza u oseltamivir dos veces al día durante cinco días (dosificación según el peso corporal).
El tiempo de alivio de los signos y síntomas de la influenza fue comparable entre Xofluza y oseltamivir. La mediana de tiempo hasta el alivio de los signos y síntomas en los participantes infectados con influenza fue de 138 horas (IC del 95 %: 117, 163) y de 150 horas (IC del 95 %: 115, 166) para los que recibieron Xofluza u oseltamivir, respectivamente. Xofluza redujo el tiempo de liberación de la influenza del cuerpo en más de dos días en comparación con el oseltamivir (replicación viral; mediana de tiempo de 24,2 horas frente a 75,8 horas, respectivamente). Xofluza fue bien tolerado y no se identificaron nuevas señales de seguridad.
Acerca de BLOCKSTONE2
BLOCKSTONE fue un estudio de fase III, doble ciego, multicéntrico, aleatorizado, controlado con placebo, de profilaxis posterior a la exposición que evaluó una dosis única de Xofluza® (baloxavir marboxil) en comparación con un placebo en miembros del hogar (adultos y niños), que vivían con alguien con influenza, confirmado por una prueba de diagnóstico rápido de influenza (el ‘paciente índice’).
Los participantes inscritos en el estudio eran miembros del hogar de alguien a quien se le había diagnosticado influenza. Los participantes fueron aleatorizados para recibir una dosis única de Xofluza (dosis según el peso corporal) o un placebo como medida preventiva contra el desarrollo de la gripe.
Xofluza mostró un efecto profiláctico estadísticamente significativo después de una dosis oral única, al reducir el riesgo de que las personas desarrollen influenza después de la exposición a un miembro del hogar infectado en un 86 % en comparación con el placebo. La proporción de hogares que desarrollaron influenza clínica confirmada por laboratorio fue del 1,9 % en los participantes tratados con Xofluza y del 13,6 % en el grupo tratado con placebo.
Xofluza fue bien tolerado en este estudio y no se identificaron nuevas señales de seguridad. El estudio fue realizado en Japón por Shionogi & Co., Ltd.
Acerca de Xofluza® (baloxavir marboxil)
Xofluza es un medicamento oral de dosis única, primero en su clase, con un mecanismo de acción innovador que ha demostrado eficacia en una amplia variedad de virus de influenza, incluida la actividad in vitro contra cepas resistentes a oseltamivir y cepas aviares (H7N9, H5N1) en estudios no clínicos.10,16,17 Xofluza es el primero de una clase de antivirales diseñados para inhibir la proteína endonucleasa cap-dependiente, que es esencial para la replicación viral.10< /sup>
Xofluza está aprobado en más de 70 países para el tratamiento de la influenza tipo A y B. En Europa, Xofluza ahora está aprobado para el tratamiento de la influenza no complicada y para la profilaxis posterior a la exposición de la influenza en niños a partir de un año y en adolescentes. y adultos Xofluza es la primera innovación en el mecanismo de acción de un antiviral antigripal aprobado por la Comisión Europea en casi 20 años.18
Evidencia clínica sólida ha demostrado el beneficio de Xofluza en varias poblaciones (niños sanos, de alto riesgo y profilaxis posterior a la exposición en personas de un año o más).1,2,10,19 Xofluza se está estudiando más en un programa de desarrollo de fase III, incluso en niños menores de un año (NCT03653364), así como para evaluar su potencial para reducir la transmisión de influenza de una persona infectada a personas sanas (NCT03969212).14,15
Xofluza fue descubierto por Shionogi & Co., Ltd. y se está desarrollando y comercializando a nivel mundial en colaboración con el Grupo Roche (que incluye a Genentech en los EE. UU.) y Shionogi & Co., Ltd. Según los términos de este acuerdo, Roche posee los derechos mundiales de Xofluza, excepto Japón y Taiwán, que serán retenidos exclusivamente por Shionogi & Co., Ltd.
Acerca de Roche en gripe
La gripe es una enfermedad infecciosa grave y representa una amenaza importante para la salud pública. Las epidemias estacionales provocan de tres a cinco millones de casos de enfermedades graves, millones de hospitalizaciones y hasta 650 000 muertes en todo el mundo cada año.4 Roche tiene una larga trayectoria en el desarrollo de medicamentos que contribuyen a la salud pública. Estamos comprometidos a traer innovación en el campo de las enfermedades infecciosas, incluida la influenza. Tamiflu® (oseltamivir) ha marcado una diferencia significativa tanto en el tratamiento de la influenza estacional como en el manejo de pandemias recientes, y estamos orgullosos de haber llevado este medicamento innovador a los pacientes. Aunque las vacunas son una importante primera línea de defensa para prevenir la influenza, se necesitan nuevas opciones médicas para la prevención (profilaxis) y el tratamiento. Roche se compromete a abordar la necesidad no satisfecha en esta área a través de su acuerdo con Shionogi & Co., Ltd. para desarrollar y comercializar Xofluza® (baloxavir marboxil).
Acerca de Roche
Fundada en 1896 en Basilea, Suiza, como uno de los primeros fabricantes industriales de medicamentos de marca, Roche se ha convertido en la empresa de biotecnología más grande del mundo y líder mundial en diagnóstico in vitro. La empresa persigue la excelencia científica para descubrir y desarrollar medicamentos y diagnósticos para mejorar y salvar la vida de las personas en todo el mundo. Somos pioneros en atención médica personalizada y queremos transformar aún más la forma en que se brinda la atención médica para tener un impacto aún mayor. Para brindar la mejor atención a cada persona, nos asociamos con muchas partes interesadas y combinamos nuestras fortalezas en Diagnóstico y Farmacia con conocimientos de datos de la práctica clínica.
En reconocimiento a nuestro esfuerzo por buscar una perspectiva a largo plazo en todo lo que hacemos, Roche ha sido nombrada una de las empresas más sostenibles de la industria farmacéutica por los índices de sostenibilidad Dow Jones por decimotercer año consecutivo. Esta distinción también refleja nuestros esfuerzos para mejorar el acceso a la atención médica junto con socios locales en todos los países en los que trabajamos.
Genentech, en los Estados Unidos, es un miembro de propiedad absoluta del Grupo Roche. Roche es el accionista mayoritario de Chugai Pharmaceutical, Japón.
Para obtener más información, visite www.roche.com.
Todas las marcas comerciales utilizadas o mencionadas en este comunicado están protegidas por ley.
Referencias
[1] Baker J, et al. Pediatr Infect Dis J. 2020;39(8):700-705.
[2] Ikematsu H, et al. N Engl J Med. 2020;383:309-320.
[3] European Medicines Agency. Xofluza. [Internet; cited December 2022]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/xofluza-0.
[4] World Health Organization. Influenza (seasonal). [Internet; cited December 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
[5] Centers for Disease Control and Prevention. Disease burden of influenza. [Internet; cited December 2022]. Available from: https://www.cdc.gov/flu/about/burden/index.html.
[6] World Health Organization. Influenza. [Internet; cited December 2022]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/influenza.
[7] World Health Organization. Joint statement – Influenza season epidemic kicks off early in Europe as concerns over RSV rise and COVID-19 is still a threat. [Internet; cited December 2022]. Available from: https://www.who.int/europe/news/item/01-12-2022-joint-statement—influenza-season-epidemic-kicks-off-early-in-europe-as-concerns-over-rsv-rise-and-covid-19-is-still-a-threat.
[8] Influenza in children. Paediatr Child Health. 2005;10(8):485-487. doi:10.1093/pch/10.8.485.
[9] Tsang T, et al. Trends Microbiol. 2016;24(2):123-133.
[10] Hayden F, et al. N Engl J Med 2018;379:913–923.
[11] Zhanwei D, et al. Nat Commun. 2020;11:2750.
[12] European Medicines Agency. Xofluza: EPAR – Medicine overview. [Internet; cited December 2022]. Available from: https://www.ema.europa.eu/en/documents/overview/xofluza-epar-medicine-overview_en.pdf.
[13] Roche. Data on File.
[14] Clinicaltrials.gov. Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms. [Internet; cited December 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03653364.
[15] Clinicaltrials.gov. Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households. [Internet; cited December 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03969212.
[16] Noshi T, et al. Antiviral Res. 2018;160:109-117.
[17] Taniguchi K, et al. Sci Rep. 2019;9:3466.
[18] Roche.com. Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years. [Internet; cited December 2022]. Available from: https://www.roche.com/media/releases/med-cor-2021-01-11.
[19] Ison, et al. Lancet Infect Dis 2020;20(10):1204–14.
DESCARGO DE RESPONSABILIDAD: La versión en español de este comunicado de prensa es una traducción del comunicado de prensa original, que está escrito en inglés, y es solo para fines informativos. En caso de discrepancia, prevalecerá la versión en inglés de este comunicado de prensa.
Relaciones con los medios del Grupo Roche
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD Phone: +41 79 407 72 58 |
Nathalie Altermatt Phone: +41 79 771 05 25 |
Karsten Kleine Phone: +41 79 461 86 83 |
Nina Mählitz Phone: +41 79 327 54 74 |
Dr. Barbara von Schnurbein Phone: +41 79 699 97 44 |
Sileia Urech Phone: +41 79 935 81 48 |
Relaciones con inversores de Roche
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Relaciones con inversores América del Norte
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
SOURCE: F. Hoffmann-La Roche Ltd
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares
- Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses
- Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию
- Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights
- North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel
- Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке
- Digi Communications NV announces the release of the Q3 2023 Financial Results
- IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home
- BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”
- Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer
- Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results
- Jifiti Granted Electronic Money Institution (EMI) License in Europe
- Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности
- VRG Components Welcomes New Austrian Independent Agent
- Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain
- Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы
- Double digit growth in global hospitality industry for Q4 2023
- ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market
- Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland
- EU-Funded CommuniCity Launches its Second Open Call
- Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas
- La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas
- Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks
- Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware
- Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations
- Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year
- Digi Communications N.V. announces the availability of the 2022 Annual Report
- Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts
- Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство
- BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility
- Russian Emigrés Amplify Pleas of “I Want You to Live” through Art
- Digi Communications NV announces the release of H1 2023 Financial Results
- Digi Communications NV Announces Investors Call for the H1 2023 Financial Results
- Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report
- “Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine
- Digi Communications N.V. announces the availability of the 2022 Annual Financial Report
- “AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam
- Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam
- Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary
- Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar
- iGulu F1: Brewing Evolution Unleashed
- Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом
- Hajj Minister meets EU ambassadors to Saudi Arabia
- Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists
- Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021
- Digi Communications N.V. announces the release of the Q1 2023 financial results
- AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE
- Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation
- Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar
- Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary
- Patients as Partners Europe Returns to London and Announces Agenda Highlights
- GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE
- Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain
- XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)
- Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper
- Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone
- Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona
- Digi Communications N.V. announces conditional stock options granted to a Director of the Company based on the general shareholders’ meeting approval from 28 December 2022
- Digi Communications N.V. announces the release of the 2022 Preliminary Financial Results
- CAMPAIGNS FOR HUMANITY: MARKETING AGENCY ANNOUNCES €10,000 AWARDS FOR RUSSIANS SUPPORTING UKRAINE
- One Year Since the Invasion: New Series Highlights Everyday People Transformed by War into Heroes
- Digi Communications N.V. announces Investors Call for the presentation of the 2022 Preliminary Financial Results
- BevZero Receives Top Environmental Certification
- Thompson Duke Industrial Attains CE Certification for its Cannabis Vaporizer Cartridge Filling Equipment
- Modern Media Hub Takes Huge Leap with Financing Help of Cap Expand Partners
- Digi Communications N.V. announces the release of the Financial Calendar for 2023
- Digi Communications N.V. announces the exercise of stock options by two of the Directors of the Company
- Tanduay Is First Asian Rum to Enter Austrian Market
- Digi Communications N.V. Announces the Resolutions of the General Shareholders’ Meeting from 28 December 2022, approving, amongst others, the 2021 Annual Accounts
- MIGUN LIFE's new personal healthcare products are unveiled, heralding the grand first debut at CES 2023
- Digi Communications N.V. announces that the Romanian version of the Annual Financial Report for the year ended December 31, 2021 for the Digi Communications N.V. Group is available
- Digi Communications N.V. Announces Convocation of the Company’s general shareholders meeting for 28 December 2022 for the approval of, among other items, the 2021 Annual Report
- Digi Communications N.V. Announces the availability of the Annual Financial Report for the year ended December 31, 2021 for Digi Communications N.V. Group
- Digi Communications N.V.’s Romanian subsidiary was designated winner of the auction organised for the allocation of certain radio frequency entitlements in 2600 MHz and 3400-3800 MHz bands
- Digi Communications NV announces the release of the Q3 2022 Financial Results
- Digi Communications N.V. announces a Subsequent Amendment of the Company’s 2022 financial calendar
- Digi Communications NV announces Investors Call for the Q3 2022 Financial Results presentation
- Sygnum Bank and Artemundi tokenize Warhol’s Marilyn Monroe artwork
- Your Daily Commutes Will be Seamless, Connected and Productive.
- The secondary market platform THELAPHANT.IO introduces, for the first time in Israel: "a stock liquidity plan" for high-tech employees and companies
- Teavaro and CDP Institute Offer Free Online Course on Identity Resolution
- Digi Communications N.V. announces a Subsequent Amendment of the Company’s 2022 financial calendar
- Digi Communications N.V. announces an Amendment of the Company’s 2022 financial calendar
- 12-month real-world achievements for Diabeloop’s Automated Insulin Delivery (AID):
- Digi Communications N.V. announces the availability of the Instruction regarding the Payment of Dividends for the Financial Year 2021
- Simplify Content za usluge organskog Content Marketinga otvara svoja vrata poduzećima da (zajedno) uspješno kreiraju kvalitetan i relevantan sadržaj za potencijalne i postojeće klijente
- Digi Communications N.V. announces the approval of interim dividend distribution and updates regarding the 2022 Financial Calendar
- A new, creativity-based educational method increases the ability to solve problems with young people, in the social field, or when building a team in the company
- Digi Communications NV announces the release of the H1 2022 Financial Results
- Mit Intelligenz geladen
- Digi Communications NV announces Investors Call for the H1 2022 Financial Results
- Digi Communications N.V. Announces the update of its 2022 Financial Calendar
- Digi Communications N.V. Announces the conclusion by the Company’s Spanish subsidiary of an amendment agreement to the facility agreement dated 26 July 2021
- Customer Data Platform Industry Grew Strongly in First Half of 2022: CDP Institute Report
- Metadeq Announces Breakthrough Non-Invasive Blood Test that Solves NASH Diagnosis Problem
- Η HBC Consulting Expert θεωρεί παράλογη την εμπλοκή του κυπριακού δικαστηρίου στην υπόθεση κληρονομιάς από τη χήρα του ολιγάρχη Μπόσοφ
- Esperto della società di consulenza HBC: le autorità italiane non hanno permesso a Katerina Bosov di vendere la villa del marito
- HBC Consulting Expert considers senseless the involvement of the Cypriot court in the case of inheritance by the widow of oligarch Bosov
- Fusion BPO Services is Opening New Center in Kosovo
- Hi-SIDE demonstrates an integrated high speed satellite data chain architecture at data rates exceeding 10 Gigabits per second
- Digi Communications N.V. announces that a joint venture of its subsidiary in Romania designated as one of the winners of the auction organized by the Belgian Institute for Postal Services and Telecommunications for the allocation of mobile spectrum frequency user rights
- KI-basierte Geldanlage für Privatpersonen – Velvet AutoInvest erhält 1,3 Mio. USD Seed-Investment
- Haizol Now Offer 3D Printing Services to Customers Worldwide
- Caravel Capital Fund Showcased At Secure Spectrum’s Hedge Fund Seminar
- Diabeloop, a key player in therapeutic AI applied to insulin delivery, announces 70 million euros new financing round to accelerate its international expansion
- Digi Communications NV Announces Availability of the 2021 Preliminary Annual Report (including the Company’s audited non-statutory Consolidated financial statements issued as per IFRS EU)
- Digi Communications N.V. Announces that conditional stock options were granted to executive directors of the Company and to directors and employees of the Company’s Romanian Subsidiary
- Caravel Capital Investments Inc. Founding Partner to Speak at Secure Spectrum Hedge Fund Seminar
- Digi Communications NV announces a correction of clerical errors by Amending the Q1 2022 Financial Report
- Digi Communications NV announces the release of Q1 2022 Financial Results
- Digi Communications N.V. announces Investors Call for the Q1 2022 Financial Results presentation
- Yield Crowd Tokenizes US $50M Real Estate Portfolio on Stellar Blockchain
- Digi Communications N.V. Announces an Amendment to the Financial Calendar for 2022
- Diabeloop presents new real-life results of DBLG1® System: Confirmed improvement in Time In Range +18.4 percentage points; Reduction of time spent in hypoglycemia to only 0.9%
- How two female entrepreneurs are redefining the lake travel industry
- Vil du være med å utvikle fremtidens bærekraftige reiseliv?
- Mettiti alla prova con la terza edizione del CASSINI Hackathon per rivitalizzare il settore turistico
- Προκαλέστε τον εαυτό σας στο 3ο CASSINI Hackathon και στοχεύστε την αναζωογόνηση του τουρισμού!
- Participez au 3e Hackathon CASSINI et relevez le défi de redynamiser le tourisme!
- 3. CASSINI Hackathon zur Neubelebung des Tourismus: Stellen Sie sich der Herausforderung!
- Írd újra Európa turizmusát a 3. CASSINI Hackathonon!
- Aceita o desafio do 3º CASSINI Hackathon para revitalizar o turismo!
- Podejmij wyzwanie! Weź udział w 3. Hackathonie CASSINI i pomóż ponownie ożywić turystykę!
- Daag jezelf uit op de 3e CASSINI Hackathon en blaas toerisme nieuw leven in
- Diabeloop adapts its self-learning, personalized insulin automatization software to be used with insulin pens
- Amadeus unveils five defining trends for the US group travel and events industry in 2022
- On World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder
- Global & Europe Mental Health Software and Devices Market to Witness a Revenue of USD 13367.12 Million by 2030 by Growing with a CAGR of 13.28% During 2021-2030; Increasing Concern for Mental Health Disorders to Drive Market Growth
- Digi Communications NV announces the release of the 2021 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the 2021 Preliminary Financial Results presentation
- At MWC in Barcelona, Amphenol will be exhibiting its wide offering for wireless service providers – including Open RAN compatible active 5G antennas
- ELIOS combined with cataract surgery delivers significant IOP reduction out to 8 years
- Tableau comparatif des pays : les caractéristiques à connaître avant de se développer à l’international
- Smart exosomes from an Australian technology leader
- Bucharest Digi Communications N.V. announces Share transaction made by an executive director of the Company with class B shares
- Transmetrics AI is Applied by DB Schenker to Improve Land Transport Network in Bulgaria
- Digi Communications N.V.: Announces repayment of an aggregate amount of approx. EUR 272 million of the Group’s financial debt
- El Liceo Europeo vence el Premio Zayed a la Sustentabilidad 2022 en Europa y Asia Central
- Framework rebrands to daappa, heralding a new phase in fintech solutions designed for private markets
- Digi Communications N.V. Announces the publishing of the Financial Calendar for 2022
- Manufacturing giant Haizol expands their offices in China
- Patients and R&D Leaders Jointly Present at EU Conference on Progress with Patient-Input to Transform Medicine Development
- Seminário Bíblico sobre “O Cumprimento da Palavra de Jesus no Mundo de Hoje”
- 'I Love fruit & veg from Europe': Weihnachten in der Schweiz ist gesund und voller Aromen
- Fidupar Now Live on Framework’s Core Solution
- Maya Miranda Ambarsari launches InterconnectDATA information platform for authentic data
- Digi Communications N.V. Announces that the offer of the Company’s Romanian subsidiary was designated winner of the auction organised for the allocation of certain radio frecquency entitlements
- New dating site aimed at people with mental health problems launches in Switzerland
- BITSCore Tests Satellite Cyber-Security and Ride-Share Algorithms on Australian Rocket
- StatusMatch.com ed Emirates collaborano per aiutare i frequenti viaggiatori italiani a tornare in volo
- StatusMatch.com and Emirates partner up to help Italian frequent flyers get back in the air
- MinDCet drivers and FTEX powertrain solutions enable EV GaN applications
- Digi Communications NV announces the release of the Q3 2021 Financial Results
- Origami and citoQualis Team up for Startups
- Digi Communications NV announces Investors Call for the Q3 Financial Results presentation
- Digi Communications N.V. announces the extraordinary general meeting’s resolution from 4 November 2021, approving the appointment of KPMG N.V. as the Company’s statutory auditor for the 2021 financial year
- Digi Communications N.V. announces The solution reached by the Bucharest Court of Appeal regarding the investigation conducted by the Romanian National Anticorruption Directorate with respect to RCS & RDS S.A., Integrasoft S.R.L. and certain of their directors
- Digi Communications N.V. Announces the results of the auction organised by the Portuguese Authority for Telecommunications
- Haizol expands its capabilities to include component assembly and product development
- EIC, the World’s Largest Multinational Innovation Program, to Invest €13.4M in Wi-Charge, a Game Changing Wireless Power Company
- European Weightlifting Federation on its way for Electoral Congress
- “Without women, We are unable to solve the world’s greatest challenges” — She Loves Tech 12 Hot Finalists ready to get their chance at the Local Pitch in South Europe!
- Significant improvement in increasing Time In Range and reducing hypoglycemia among people equipped with Diabeloop DBLG1
- Digi Communications N.V. Announces the Convocation of the Company’s Extraordinary General Meeting of Shareholders on 4 November 2021 in order to appoint KPMG N.V. as the Company’s new statutory auditor for the financial year 2021
- Unit of Measure enters partnership with Stibo Systems
- Haizol, metal manufacturing giant, launch a brand new website which is both user friendly and interactive
- Groundbreaking Immersive Experience from Samsung and Artist Michael Murphy Reveals a New Perspective for Visual Entertainment Through the Stunningly Slim Neo QLED TV
- Collaboration between Airbus and Neural Concept
- Archpriest Nikolay Balashov on Patriarch Bartholomew’s speeches in Kiev
- ABB's Peter Voser joins Xynteo's Europe Delivers partnership as it new Chairman
- Digi Communications NV announces that a new stock option programme was approved
- Leverage the benefits of digital manufacturing with Haizol
- Digi Communications NV announces the release of the H1 2021 Financial Results
- Digi Communications NV announces Investors Call on the Financial Results for H1 2021
- Rockegitarist-Sensasjon Rocky Kramer Har Fått Hovedrollen I Mutt Productions Filmen Rockin’ In Time
- Dispatch.d Offers Unique US Market Entry Services for European Impact Brands
- CSA Research’s New Localization Intelligence Analyzer, powered by LocHub, Helps Organizations Improve their Website’s Effectiveness for Global Customers
- Customer Data Platform Industry Accelerated During Pandemic: CDP Institute Report
- Digi Communications N.V. announces that two of its subsidiaries entered into two facility agreements
- Introducing Cap Expand Partners, Helping Business Leaders Break International Barriers
- Hong Kong’s Innovation and Technology Venture Fund Becomes Strategic Financial Investor of Ignatica
- Cure for prostate cancer on the horizon
- Fanpictor signs multi-year partnership with Royal Belgian Football Association
- Fanpictor unterzeichnet mehrjährige Partnerschaft mit dem Königlich Belgischen Fussballverband
- Fanpictor signe un partenariat pluriannuel avec la Royal Belgian Football Association
- Fanpictor firma una colaboración de varios años con la Real Federación Belga de Fútbol
- Fanpictor firma una partnership pluriennale con la Royal Belgian Football Association
- Fanpictor tekent meerjarige partnership met Koninklijke Belgische Voetbalbond
- Launch of the New Akenza Platform
- De zelflerende algoritme DBLG1®: eenvoudig te gebruiken voor een optimale en gepersonaliseerde behandeling van diabetes type 1
- Launch of the Anna Lindh Foundation Virtual Marathon for Dialogue!
- Digi Communications N.V. announces the exercise of stock options by the Executive Director of the Company pursuant to the decision of the Company’s general meeting of shareholders dated 30 April 2020 and in accordance with the stock option plan approved at the level of the Company in 2017
- New research unlocks long tail growth opportunity for the tech industry
- Digi Communications NV announces the availability of the instructions on the 2020 share dividend payment
- Digi Communications NV announces that conditional stock options were granted to several Directors of the Company based on the approval of the general meeting of shareholders from 18 May 2021
- Digi Communications N.V. Announces the Company’s General Shareholders Meeting resolutions adopted on 18 May 2021 approving, amongst others, the 2020 Annual Accounts
- Digi Communications N.V. (“Digi”) announces the Q1 2021 Financial results
- Digi Communications NV announces Investors Call for the Q1 2021 Financial Results
- Digi Communications N.V. announces an Amendment to the 2021 Financial Calendar
- Fastpayhotels Hits an Industry Milestone by Connecting 500 Hotels Per Day Through DerbySoft Technology
- 4 ways to build a more flexible supply chain
- Join the world's leading virtual CBD event for FREE
- DEEPENING STRATEGIC RELATIONSHIP BETWEEN UBC AND PIONEERING DECENTRALISED PLATFORM, MANYONE
- Mono Solutions recognizes Norwegian small business agency with best website 2021 award
- Mono Solutions and Xrysos Odigos unlock new opportunities for small businesses
- Behind the scenes of a 10,000-people online conference: creating a live-event atmosphere and leveraging cybersecurity software
- Largest Supply Chain for Face masks, FFP2, FFP3 and cloth masks
- TRANSMAR AND TRANSMETRICS SIGN DEAL FOR STATE-OF-THE-ART LOGISTICS COLLABORATION
- Amendment of Digi Communications N.V. Financial Calendar for 2021
- 4iG and Digi Communications NV’s Romanian subsidiary have entered into a term sheet with regards to a potential acquisition by 4iG of DIGI Group’s Hungarian operations
- “Building Healthy Relationships and Enhancing Gender Equality”: Young women from Cyprus, Egypt, Lebanon and Jordan come together
- Bring Ventures investit dans Crossborderit (CBIT), DDP et une solution de commerce électronique
- Bring Ventures investiert in Crossborderit (CBIT), eine DDP (geliefert verzollt) und E-Commerce Lösung
- Bring Ventures invests in Crossborderit (CBIT), DDP and ecommerce solution
- Lionspeed GP with Patrick Kolb and Lorenzo Rocco joins forces with CarCollection Motorsport in 2021
- Eurekos, ein klassenbester LMS-Anbieter, hat seine Position im renommierten Fosway 9-Grid™ für Lernsysteme verbessert
- Eurekos, en førsteklasses LMS-udbyder, har forstærket sin position på den prestigefyldte Fosway 9-Grid™ for læringssystemer
- Eurekos, ein erstklassiger LMS-Anbieter, hat seine Position auf dem renommierten Fosway 9-Grid™ für Lernsysteme weiter ausgebaut
- Digi Communications N.V. announces Share transaction made by an executive director of the Company with class B shares
- Digi Communications N.V.: Announces an Amendment to the Financial Calendar for 2021
- Ideanomics Invests $13M in Italian EV Motorcycle Company, Energica
- DigiSky and Asman Technology Announce Global Reseller Agreement
- Neowintech - O Marketplace Da Sua Próxima Solução Financeira
- Neowintech - Il Marketplace per la tua prossima soluzione finanziaria
- PIONEERING DECENTRALISED SECURE MESSAGING PLATFORM MANYONE ANNOUNCES STRATEGIC RELATIONSHIP WITH UNIVERSITY COLLEGE LONDON CENTRE BLOCKCHAIN TECHNOLOGY
- Digi Communications NV announces the release of the 2020 Preliminary Financial Results
- Fraunhofer IGD develops automated robotic arm to scan cultural objects in 3D, now cooperating with Phase One
- Adapt Fast or Disappear – Choosing the Right Supplier
- Digi Communications NV announces Investors Call for the 2020 Preliminary Financial Results
- A URSAPHARM Arzneimittel e a CEBINA anunciam uma parceria com vista a reaproveitar o anti-histamínico azelastina para combater a COVID-19
- URSAPHARM Arzneimittel et CEBINA annoncent un partenariat pour reconvertir l'antihistaminique azélastine afin de lutter contre la COVID-19
- URSAPHARM Arzneimittel y CEBINA anuncian una colaboración para readaptar el antihistamínico azelastine para combatir la COVID-19
- URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19
- ANIL UZUN Will Launch Bass Guitar Lessons Series on Youtube
- Henrik Stampe Appointed CEO for Mono Solutions
- Anna Mossberg leder Nordens största privata AI-lab i Sverige: "Utan AI riskerar svenska företag att förlora sin konkurrensfördel."
- What COVID-19 has taught us about manufacturing & the importance of a digital online marketplace
- Digi Communications N.V. announces: the Supreme Court of Hungary dismissed the Company’s appeal related to the 5G Tender procedure
- Customer Data Platform Industry to Reach $1.5 Billion in 2021: CDP Institute Report
- Editor's pick archive....
GreenMantra Technologies Announces Exclusive Distribution Relationship with HARKE GROUP